Zinc Deficiency Induces Vascular Pro-Inflammatory Parameters Associated with NF-κB and PPAR Signaling

Journal of the American College of Nutrition

Volumn 27, Issue 5, 2008, Pages 577-587

  Shen, Huiyun ^a   Oesterling, Elizabeth ^a   Hennig, Bernhard ^a,b   Stromberg, Arnold ^c   Toborek, Michal ^d   MacDonald, Ruth ^e  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b Molecular and Cell Nutrition Laboratory   (United States)

^c College of Agriculture Departments of Statistics ^*  (United States)

^d Department of Neurosurgery ^*  (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Endothelial cells; Inflammation; LDL R deficient mouse; NF B; PPAR; Zinc deficiency

Indexed keywords

CAFFEIC ACID PHENETHYL ESTER; CYCLOOXYGENASE 2; DNA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CAFFEIC ACID DERIVATIVE; PHENYL CAFFEATE; UNCLASSIFIED DRUG; ZINC;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DNA BINDING; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HYPOTHESIS; IN VIVO STUDY; INHIBITION KINETICS; MALE; MODULATION; MONOCYTE; MOUSE; NONHUMAN; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; VASCULAR CAPACITY; VASCULAR DISEASE; VASCULITIS; ZINC DEFICIENCY; ANIMAL; ATHEROSCLEROSIS; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETICS; INFLAMMATION; METABOLISM; PHYSIOLOGY;

MUS;

ANIMALS; ATHEROSCLEROSIS; CAFFEIC ACIDS; CELL ADHESION; CELLS, CULTURED; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; MICE; MONOCYTES; NF-KAPPA B; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, LDL; THIAZOLIDINEDIONES; ZINC;

EID: 58149393439     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2008.10719741     Document Type: Article

References (67)

1. Glass CK, Witztum JL: Atherosclerosis. the road ahead. Cell 104: 503-516, 2001.
2. Hennig B, Meerarani P, Ramadass P, Toborek M, Malecki A, Slim R, McClain CJ: Zinc nutrition and apoptosis of vascular endothelial cells: implications in atherosclerosis. Nutrition 15: 744-748, 1999.
3. Cousins RJ: A role of zinc in the regulation of gene expression. Proc Nutr Soc 57: 307-311, 1998.
4. O'Dell BL: Role of zinc in plasma membrane function. J Nutr 130: 1432S-1436S, 2000.
5. Oteiza PI, Mackenzie GG: Zinc, oxidant-triggered cell signaling, and human health. Mol Aspects Med 26: 245-255, 2005.
6. Maret W: Zinc coordination environments in proteins determine zinc functions. J Trace Elem Med Biol 19: 7-12, 2005.
7. Liuzzi JP, Cousins RJ: Mammalian zinc transporters. Annu Rev Nutr 24: 151-172, 2004.
8. Cousins RJ, Liuzzi JP, Lichten LA: Mammalian zinc transport, trafficking, and signals. J Biol Chem 281: 24085-24089, 2006.
9. Singh RB, Gupta UC, Mittal N, Niaz MA, Ghosh S, Rastogi V: Epidemiologic study of trace elements and magnesium on risk of coronary artery disease in rural and urban Indian populations. J Am Coll Nutr 16: 62-67, 1997.
10. Singh RB, Niaz MA, Rastogi SS, Bajaj S, Gaoli Z, Shoumin Z: Current zinc intake and risk of diabetes and coronary artery diseaseand factors associated with insulin resistance in rural and urban populations of North India. J Am Coll Nutr 17: 564-570, 1998.
11. Vlad M, Caseanu E, Uza G, Petrescu M: Concentration of copper, zinc, chromium, iron and nickel in the abdominal aorta of patients deceased with coronary heart disease. J Trace Elem Electrolytes Health Dis 8: 111-114, 1994.
12. Hennig B, Meerarani P, Toborek M, McClain CJ: Antioxidant-like properties of zinc in activated endothelial cells. J Am Coll Nutr 18: 152-158, 1999.
13. Prasad AS, Bao B, Beck FW, Kucuk O, Sarkar FH: Antioxidant effect of zinc in humans. Free Radic Biol Med 37: 1182-1190, 2004.
14. Oteiza PI, Clegg MS, Zago MP, Keen CL: Zinc deficiency induces oxidative stress and AP-1 activation in 3T3 cells. Free Radic Biol Med 28: 1091-1099, 2000.
15. Meerarani P, Reiterer G, Toborek M, Hennig B: Zinc modulates PPARgamma signaling and activation of porcine endothelial cells. J Nutr 133: 3058-3064, 2003.
16. Reiterer G, Toborek M, Hennig B: Peroxisome proliferator activated receptors alpha and gamma require zinc for their antiinflammatory properties in porcine vascular endothelial cells. J Nutr 134: 1711-1715, 2004.
17. Shen H, Macdonald R, Bruemmer D, Stromberg A, Daugherty A, Li XA, Toborek M, Hennig B: Zinc Deficiency Alters Lipid Metabolism in LDL Receptor Deficient Mice Treated with Rosiglitazone. J Nutr 137: 2339-2345, 2007.
18. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C: Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 85: 267-273, 2003.
19. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 114: 1564-1576, 2004.
20. Hihi AK, Michalik L, Wahli W: PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 59: 790-798, 2002.
21. Lee MS, Kliewer SA, Provencal J, Wright PE, Evans RM: Structure of the retinoid X receptor alpha DNA binding domain: a helix required for homodimeric DNA binding. Science 260: 1117-1121, 1993.
22. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86: 280-288, 2001.
23. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89: 2728-2735, 2004.
24. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C: Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 483: 79-93, 2004.
25. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK: Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523-531, 2000.
26. Levi Z, Shaish A, Yacov N, Levkovitz H, Trestman S, Gerber Y, Cohen H, Dvir A, Rhachmani R, Ravid M, Harats D: Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab 5: 45-50, 2003.
27. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106: 679-684, 2002.
28. Meisner F, Walcher D, Gizard F, Kapfer X, Huber R, Noak A, Sunder-Plassmann L, Bach H, Haug C, Bachem M, Stojakovic T, Marz W, Hombach V, Koenig W, Staels B, Marx N: Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebocontrolled trial. Arterioscler Thromb Vasc Biol 26: 845-850, 2006.
29. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, Wolfe ML, Rader DJ: Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26: 624-630, 2006.
30. Hennig B, Shasby DM, Fulton AB, Spector AA: Exposure to free fatty acid increases the transfer of albumin across cultured endothelial monolayers. Arteriosclerosis 4: 489-497, 1984.
31. Toborek M, Lee YW, Garrido R, Kaiser S, Hennig B: Unsaturated fatty acids selectively induce an inflammatory environment in human endothelial cells. Am J Clin Nutr 75: 119-125, 2002.
32. Reeves PG, Rossow KL, Lindlauf J: Development and testing of the AIN-93 purified diets for rodents: results on growth, kidney calcification and bone mineralization in rats and mice. J Nutr 123: 1923-1931, 1993.
33. Emery MP, Browning JD, O'Dell BL: Impaired hemostasis and platelet function in rats fed low zinc diets based on egg white protein. J Nutr 120: 1062-1067, 1990.
34. Choi W, Eum SY, Lee YW, Hennig B, Robertson LW, Toborek M: PCB 104-induced proinflammatory reactions in human vascular endothelial cells: relationship to cancer metastasis and atherogenesis. Toxicol Sci 75: 47-56, 2003.
35. Slim R, Toborek M, Robertson LW, Hennig B: Antioxidant protection against PCB-mediated endothelial cell activation. Toxicol Sci 52: 232-239, 1999.
36. Lim EJ, Kim CW: Functional characterization of the promoter region of the chicken elongation factor-2 gene. Gene 386: 183-190, 2007.
37. Chung HY, Sung B, Jung KJ, Zou Y, Yu BP: The molecular inflammatory process in aging. Antioxid Redox Signal 8: 572-581, 2006.
38. Vasto S, Mocchegiani E, Malavolta M, Cuppari I, Listi F, Nuzzo D, Ditta V, Candore G, Caruso C: Zinc and inflammatory/immune response in aging. Ann N Y Acad Sci 1100: 111-122, 2007.
39. Prasad AS: Zinc: mechanisms of host defense. J Nutr 137: 1345-1349, 2007.
40. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108: 1912-1916, 2003.
41. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 108: 2034-2040, 2003.
42. Thomson MJ, Puntmann V, Kaski JC: Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? Cardiovasc Drugs Ther 21: 195-210, 2007.
43. Li N, Karin M: Is NF-kappaB the sensor of oxidative stress? Faseb J 13: 1137-1143, 1999.
44. Monaco C, Paleolog E: Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 61: 671-682, 2004.
45. Baldwin AS Jr: Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107: 3-6, 2001.
46. Brostjan C, Anrather J, Csizmadia V, Natarajan G, Winkler H: Glucocorticoids inhibit E-selectin expression by targeting NF-kappaB and not ATF/c-Jun. J Immunol 158: 3836-3844, 1997.
47. Bishop-Bailey D, Mitchell JA, Warner TD: COX-2 in cardiovascular disease. Arterioscler Thromb Vasc Biol 26: 956-958, 2006.
48. Kaneko M, Hayashi J, Saito I, Miyasaka N: Probucol downregulates E-selectin expression on cultured human vascular endothelial cells. Arterioscler Thromb Vasc Biol 16: 1047-1051, 1996.
49. Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BB: Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci USA 93: 9090-9095, 1996.
50. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative crosstalk with transcription factors NF-kappaB and AP-1. J Biol Chem 274: 32048-32054, 1999.
51. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, Kim TS: Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem 275: 32681-32687, 2000.
52. Delerive P, Gervois P, Fruchart JC, Staels B: Induction of IkappaBalpha expression as a mechanism contributing to the antiinflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275: 36703-36707, 2000.
53. Lucas AD, Greaves DR: Atherosclerosis: role of chemokines and macrophages. Expert Rev Mol Med 3: 1-18, 2001.
54. Maret W, Krezel A: Cellular zinc and redox buffering capacity of metallothionein/thionein in health and disease. Mol Med 13: 371-375, 2007.
55. Kang YJ: Metallothionein redox cycle and function. Exp Biol Med (Maywood) 231: 1459-1467, 2006.
56. Maret W: Zinc coordination environments in proteins as redox sensors and signal transducers. Antioxid Redox Signal 8: 1419-1441, 2006.
57. Giacconi R, Bonfigli AR, Testa R, Sirolla C, Cipriano C, Marra M, Muti E, Malavolta M, Costarelli L, Piacenza F, Tesei S, Mocchegiani E: 647 A/C and 1245 MT1A polymorphisms in the susceptibility of diabetes mellitus and cardiovascular complications. Mol Genet Metab 94: 1-3, 2008.
58. Kaul D: Molecular link between cholesterol, cytokines and atherosclerosis. Mol Cell Biochem 219: 65-71, 2001.
59. Dinarello CA: Proinflammatory cytokines. Chest 118: 503-508, 2000.
60. Opal SM, DePalo VA: Anti-inflammatory cytokines. Chest 117: 1162-1172, 2000.
61. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P: C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 21: 1787-1803, 2003.
62. Signorelli SS, Mazzarino MC, Spandidos DA, Malaponte G: Proinflammatory circulating molecules in peripheral arterial disease. Int J Mol Med 20: 279-286, 2007.
63. Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ, van Snick J, Kuiper J: Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112: 1054-1062, 2005.
64. Ito T, Ikeda U: Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy 2: 257-265, 2003.
65. Reiterer G, MacDonald R, Browning JD, Morrow J, Matveev SV, Daugherty A, Smart E, Toborek M, Hennig B: Zinc deficiency increases plasma lipids and atherosclerotic markers in LDLreceptor-deficient mice. J Nutr 135: 2114-2118, 2005.
66. Siebenlist U, Franzoso G, Brown K: Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10: 405-455, 1994.
67. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683, 1996.